Ascent Industries Co. is focusing on growth through its customer-embedded Chemical-as-a-Service (CaaS) model and a recent acquisition in the Midwest. The acquisition adds formulation capabilities and offers opportunities for sourcing, insourcing, and cross-selling within its existing platform. The company’s unused capacity can support this expansion without major new plant investments. The potential for revenue growth depends on management's ability to improve profit margins, making it a speculative buy based on future earnings prospects.
Celldex Therapeutics received a Buy rating upgrade from H.C. Wainwright, with the price target raised to $64 from $42, following successful Phase 3 clinical trials of barzolvolimab. The drug showed rapid and lasting benefits for patients with a chron...
Shopify and Meta have partnered to integrate Shopify's Shop Pay accelerated checkout solution with Meta's Muse AI assistant, enabling users to shop and check out easily across all Shopify stores. This collaboration aims to enhance the online shopping...
KB Home reported a 20% drop in Q3 revenue to $1.3 billion and a 19% decline in homes delivered due to a challenging housing market with higher mortgage rates and economic uncertainty. Despite these headwinds, the company improved its housing gross pr...
Blue Owl Credit Income Corp. has amended and extended its senior secured revolving credit facility, increasing its capacity from $3.9 billion to $4.2 billion and extending maturity to September 2031. The interest rate was reduced, and several lenders...
Nomad Foods will hold an Analyst and Investor Day at the New York Stock Exchange on October 6, 2026, where its management team, including CEO Dominic Brisby and CFO Ruben Baldew, will present a multi-year Value Creation Plan. The plan will outline gr...
